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ABSTRACT 
Synthesis of a series of various 1-(6-chlorobenzo[d]thiazol-2-yl)-2-(disubstitutedmethylene)hydrazine derivatives (7a-7e)have been done. 
Synthesis of a series of intermediates (3 and 5) have been also done, 6-Chloro-2-amine-1,3-benzothiazole (3), 2-hydrazino-6-chloro-1, 3-
benzothiazole (5) and final product (7a-7e), 1-(6-chlorobenzo[d]thiazol-2-yl)-2-(diphenylmethylene) hydrazine (7a), 1-(6-chlorobenzo 
[d]thiazol-2-yl)-2-(propan-2-ylidene) hydrazine (7b), (E)-2-(butan-2-ylidene)-1-(6-chlorobenzo[d]thiazol-2-yl)hydrazine (7c), (Z)-1-(6-
chlorobenzo[d]thiazol-2-yl)-2-(cyclohexylmethylene) hydrazine (7d), 2-(6-chlorobenzo[d]thiazol-2-yl)-1-(7,7- dimethylbicyclo [2,2,1] heptan-
2-ylidene)hydrazine (7e). Spectral analysis of all intermediates and final products has been done by IR and NMR. After spectral  analysis, 
antibacterial activity has been screened against S. aurius and E. coli bacterias.  
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1. INTRODUCTION 
Antimicrobial agents are those which treat infection by 
suppressing or destroying the causative microorganisms 
such as bacteria, mycobacteria, fungi, protozoa or viruses 
without significant effect on host tissues.1 The use of 
antimicrobial agents in food animals for growth promotion 
that belong to classes of antimicrobial agents used in 
humans should be terminated2. 
Some benzothiazole derivatives (drugs) are clinically used 
such as Riluzole, Thioflavin, Pittsdurgh compound B, 
Ethoxzolamine, Pramipexole, Dimazole, Flutemetol and 
Dithiazanine Iodide. 
There are no treatments available for infections caused by 
many of the antibiotic-resistant bacteria, and resistance to 
commonly used antibiotics is steadily increasing3. 
Tigecyclin is the first antibiotic approved in a new class 
called glycylcyclines and is indicated for the treatment of 
complicated intra-abdominal infections and complicated 
skin and skin structure infections in adults4. 
Ceftobiprole is resistant to staphylococcal β-lactamase. It is 
used in adults for the treatment of complicated skin and skin 
structure infection5. 
Benzothiazole ring containing compounds which are 
involved in research targeted for new compounds that 
having good biological activities such as antitumor6, 
antimicrobial7, anti-inflammatory, anti-tubercular, anti-HIV8, 
anti-malarial9,  anti-convulsant10, anthelmintic, anti-oxidants 
and analgesic. 
In addition benzothiazole ring is present in various natural 
compounds that are biologically active. 
A series of various derivatives of final products 1-(6-
chlorobenzo[d]thiazol-2-yl)-2-(diphenylmethylene) 
hydrazine (7a), 1-(6-chlorobenzo [d]thiazol-2-yl)-2-
(propan-2-ylidene) hydrazine (7b), (E)-2-(butan-2-ylidene)-
1-(6-chlorobenzo[d]thiazol-2-yl)hydrazine (7c), (Z)-1-(6-
chlorobenzo[d]thiazol-2-yl)-2-(cyclohexylmethylene) 
hydrazine (7d), 2-(6-chlorobenzo[d]thiazol-2-yl)-1-(7,7- 
dimethylbicyclo [2,2,1] heptan-2-ylidene)hydrazine (7e) has 
been synthesized by placing 2-Hydrazino amino 
benzothiazole and ketone compound (6a-e) in equimolar 
conc. in a RBF. Ethanol (20 ml) was added in the mixture and 
the reaction mixture was refluxed for 10-15 hrs. All the 
compounds synthesized have been characterized by spectral 
data and antibacterial activity has been done against 
Gram+ve S. aurius and Gram-ve E. coli bacterias by standard 
procedure using broth dilution method and minimum 
inhibitory concentration was determined by visual 
comparison with the negative control tubes. 
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2. EXPERIMENTAL 
2.1 Synthesis of 2-amine -6-chloro-1,3-benzothiazole (3) 
Cl
NH2
+ KSCN
Glacial Acetic Acid
S
N
NH2
Cl
Br2 (10-15
0C)
 
1                       2                                                                   3 
Figure 1: Synthesis of 2-amine -6-chloro-1,3-benzothiazole (3) 
 
Procedure11 
Triturate the mixture of p-chloroaniline (20g,0.156 moles) 
and potassium thiocyanate (18.19g, 0.187 moles) in motor 
pastle for 10-15 min. Add cold acetic acid (50ml) in to 
mortar and transfer this mixture in RBF, stirred  the mixture 
at 10-15⁰C then add cold acetic bromine mixture (10ml 
acetic acid and bromine) in 2-3 hr. After completion of 
bromine addition stirred the mixture for 10-15 minute. The 
reaction was monitored by TLC. Remove the RBF and keep 
overnight in to freeze.  
Work up 
In the overnight reaction mixture add 10ml H2O and 5ml 
acetic acid. Heat the reaction mixture till cease of pungent 
smell of acetic acid. Cool this mixture and filter, the solid was 
removed and liquid was collected. The liquid was neutralize 
with ammonia dropwise at 5-10⁰C. The precipitated solid 
was collected by filtration. The white solid was collected as 
pure product. 
Yield                       : 84.78% 
Melting point       : 58-600C 
TLC                         : Silica gel G; Hexane: Ethyl acetate (1:1) 
                                   Rf = 0.534 
IR (Spectrum 1)       : 3838, 3617, 2360, 1779, 1652, 1617, 
1532, 1436, 1387, 1274 Cm-1
 
 
2.2 Synthesis of 2-hydrazino-6-chloro-1, 3-benzothiazole   (5)    
S
N
NH2
Cl
+ NH2NH2.H2O
Conc.Hcl
Ethylene glycol
S
N
NH.NH2
Cl  
3                                                4                                                         5 
Figure 2: Synthesis of 2-hydrazino-6-chloro-1,3-benzothiazole 
 
Procedure12 
The obtained compound of  3 (5.00 gm,0.0264 moles) was 
dissolved in ethylene glycol (20 ml ) and Conc. HCl (10 ml) 
was added drop by drop in this mixture, now cold hydrazine 
hydrate(10 ml)  was added in this mixture. The reaction 
mixture was refluxed for 15 hr. 
Work up: 
Cool the mixture and pour this reaction mixture in to 
crushed ice. The precipitate was obtained and the 
precipitated compound was filtered under vacuum. 
 
Yield                      : 82.63% 
Melting point      : 55-58⁰C 
TLC                        : Silica gel G; Hexane: Ethyl acetate (1:1) 
                                  Rf = 0.567 
IR (Spectrum 2)      : 3734, 3674, 2954, 2411, 1759, 1716, 
1651, 1557, 1521, 1497 Cm-1 
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2.3 Synthesis of final products (7a-e) 
General scheme 
 
Cl S
N
NHNH2 + C O
R1
R2
Ethanol
Reflux
S
N
NHN
R1
R2
Cl  
               5                                        6a-e                                       7a-e 
Figure 3: General synthetic scheme for final product 
 
Procedure:13 
The obtained compound 2-Hydrazino amino benzothiazole (compound 5) and ketone compound (6a-e) was taken in equimolar 
conc. in a RBF. Ethanol (20 ml) was added in the mixture and the reaction mixture was refluxed for 10-15 hrs. The reaction was 
monitored by TLC. 
Work up: 
Cool the mixture, the precipitate was collected. The product was purified by column chromatography (Ethylacetate: hexane) to 
give the final product. 
Sr. No. Compound Name R1 R2 
1 7a 1-(6-chlorobenzo[d]thiazol-2-yl)-2-
(diphenylmethylene) hydrazine 
-C6H5 -C6H5 
2 7b 1-(6-chlorobenzo [d]thiazol-2-yl)-2-(propan-
2-ylidene) hydrazine 
-CH3 -CH3 
3 7c (E)-2-(butan-2-ylidene)-1-(6-
chlorobenzo[d]thiazol-2-yl)hydrazine 
-CH3 -C2H5 
 
(Z)-1-(6-chlorobenzo[d]thiazol-2-yl)-2-(cyclohexylmethylene) hydrazine (7d). 
 
2-(6-chlorobenzo[d]thiazol-2-yl)-1-(7, 7- dimethylbicyclo [2.2.1] heptan-2-ylidene)hydrazine (7e). 
2.3.1. Synthesis of 1-(6-chlorobenzo[d]thiazol-2-yl)-2-(diphenylmethylene) hydrazine (7a): 
 
Cl S
N
NHNH2 + C O
C6H5
C6H5
Ethanol
Reflux
S
N
NHN
C6H5
C6H5
Cl  
                  5                                       6a                                                 7a 
Figure 4: Synthesis of 1-(6-chlorobenzo[d]thiazol-2-yl)-2-(diphenylmethylene) hydrazine 
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Procedure13 
The obtained compound 2-Hydrazino amino-6-chloro-1,3-
benzothiazole (compound 5) (0.5gm,0.0024moles) and 
benzophenone (compound 6a) (0.43gm,0.0024moles) was 
taken in a RBF. Ethanol (20 ml) was added in the mixture 
and the reaction mixture was refluxed for 10-15 hrs. The 
reaction was monitored by TLC. Cool the mixture, the 
precipitate was collected. The product was purified by 
column chromatography. 
Yield                  : 83.67% 
Melting point  : 55-57⁰C 
TLC                   : Silica gel G; Hexane: Ethyl acetate (7:3) 
                              Rf = 0.514 
IR (Spectrum 3): 3800, 3701, 3648, 2398, 1828, 1771, 1716, 
1636, 1557 Cm-1
 
 
2.3.2 Synthesis of 1-(6-chlorobenzo[d]thiazol-2-yl)-2-(propan-2-ylidene)hydrazine (7b) : 
 
Cl S
N
NHNH2 + C O
H3C
H3C
Ethanol
Reflux
S
N
NHN
CH3
CH3
Cl  
                     5                                    6b                                                 7b 
Figure 5: Syntesis of 1-(6-chlorobenzo[d]thiazol-2-yl)-2-(propan-2-ylidene) hydrazine 
 
Procedure13 
The obtained compound 2-Hydrazino amino-6-chloro-1,3-
benzothiazole (compound 5) (0.5gm, 0.0024moles) and 
acetone (compound 6b) (0.176ml, 0.0024moles) was taken 
in a RBF. Ethanol (20 ml) was added in the mixture and the 
reaction mixture was refluxed for 10-15 hrs. The reaction 
was monitored by TLC. Cool the mixture, the precipitate was 
collected. The product was purified by column 
chromatography. 
Yield                  : 79.83% 
Melting point  : 57-600C 
TLC                   : Silica gel G; Hexane: Ethyl acetate (7:3) 
                             Rf = 0.587 
IR (Spectrum 4): 3819, 3749, 3648, 2935, 2359, 1670, 1615, 
1596, 1418, 1338, 1263 Cm-1  
1H NMR (Spectrum 5): δ ppm 7.22-7.59 (m, 3H, Ar-H), 1.99-
2.05 (s, 6H, CH3*2) 
13C NMR (Spectrum 6)   : δ ppm. 169.29, 151.01, 127.21, 
126.37, 120.88, 119.33, 77.42, 77.00, 76.58, 25.10, 21.51, 
17.03
 
2.3.3  Synthesis of (E)-2-(butan-2-ylidene)-1-(6-chlorobenzo[d]thiazol-2-yl) hydrazine     (7c ): 
 
Cl S
N
NHNH2 + C O
H3C
Ethanol
Reflux
S
N
NHN
CH3
C2H5
Cl
C2H5
 
                      5                                 6c                                                7c 
Figure 6: Synthesis of  (E)-2-(butan-2-ylidene)-1-(6-chlorobenzo[d]thiazol-2-yl) hydrazine 
 
Procedure13 
The obtained compound 2-Hydrazino amino-6-chloro-1,3-
benzothiazole (compound 5) (0.5gm,0.0024moles) and Ethyl 
methyl ketone 6c (0.215ml,0.0024moles) was taken in a 
RBF. Ethanol (20 ml) was added in the mixture and the 
reaction mixture was refluxed for 10-15 hrs. The reaction 
was monitored by TLC. Cool the mixture, the precipitate was 
collected. The product was purified by column 
chromatography. 
Yield                  : 84.97% 
Melting point: 55-600C 
TLC                    : Silica gel G; Hexane: Ethyl acetate (7:3) 
                              Rf = 0.535 
IR (Spectrum 7): 3766, 3674, 2927, 2397, 1800, 1733, 1683, 
1661, 1541, 1456, 1396 Cm-1 
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2.3.4 Synthesis of (Z)-1-(6-chlorobenzo[d]thiazol-2-yl)-2-(cyclohexylmethylene) hydrazine (7d): 
S
N
NHN
Cl
Cl S
N
NHNH2 +
Ethanol
Reflux
O
 
                      5                                 6d                                                  7d 
Figure 7: Synthesis of (Z)-1-(6-chlorobenzo[d]thiazole-2-yl)-2-(cyclohexylmethylene) hydrazine 
 
Procedure13 
The obtained compound 2-Hydrazino amino-6-chloro-1,3-
benzothiazole  (compound 5) (0.5gm,0.0024moles) and 
Cyclohexanone (compound 6d) (0.248ml,0.0024moles) was 
taken in a RBF. Ethanol (20 ml) was added in the mixture 
and the reaction mixture was refluxed for 10-15 hrs. The 
reaction was monitored by TLC. Cool the mixture, the 
precipitate was collected. The product was purified by 
column chromatography. 
Yield                  : 83.34% 
Melting point: 53-550C 
TLC                   : Silica gel G; Hexane: Ethyl acetate (7:3) 
                             Rf = 0.546 
IR (Spectrum 8): 3734, 3674, 2945, 2360, 1697, 1623, 1558, 
1521, 1362, 1288 Cm-1 
 
2.3.5 Synthesis of (E)-2-(6-chlorobenzo[d]thiazol-2-yl)-1-(7,7-dimethylbicyclo [2.2.1] heptan-2-ylidene) hydrazine 
(7e) : 
        
Cl S
N
NHNH2+
N
NH
S
N
Cl
O                                                                                                                                                  
                5                                       6e                                             7e 
Figure 8: Synthesis of (E)-2-(6-chlorobenzo[d]thiazol-2-yl)-1-(7,7-dimethylbicyclo[2.2.1] heptanes-2-
ylidene)hydrazine 
 
Procedure13 
The obtained compound 2-Hydrazino amino-6-chloro-1,3-
benzothiazole (compound 5) (0.5gm,0.0024moles) and 
Camphor (compound 6e) (0.365gm,0.0024moles) was taken 
in a RBF. Ethanol (20 ml) was added in the mixture and the 
reaction mixture was refluxed for 10-15 hrs. The reaction 
was monitored by TLC. Cool the mixture, the precipitate was 
collected. The product was purified by column 
chromatography. 
 Yield                  : 82.87% 
Melting point  : 55-580C 
TLC                   : Silica gel G; Hexane: Ethyl acetate (7:3) 
                             Rf = 0.574 
IR (Spectrum 9): 3766, 3724, 2955, 2821, 2384, 2017, 1967, 
1901, 1799, 1766 Cm-1 
3. BIOLOGICAL SCREENING 
Antimicrobial testing  
Activity of antimicrobial agents may be demonstrated under 
suitable conditions by their inhibitory effect on 
microorganisms. The antimicrobial activity of the 
synthesized compounds (7a-7e) was carried out by standard 
procedure using broth dilution method and minimum 
inhibitory concentration was determined by visual 
comparison with the negative control tubes.  
Detailed test procedure: 
(i) Stock Solutions of test compounds and standard drug 
Compounds were taken as test samples along with a 
standard Streptomycin sample. Weight taken in the range of 
8-20 mg of each test compound and was dissolved in 1 ml of 
DMSO. For preparing stock solution of Streptomycin, 10 mg 
of Streptomycin was dissolved in 1 ml of water.    
(ii) Test organism 
The organisms employed in the in vitro testing of the 
compounds were Escherichia coli and S. aureus. All the 
cultures were maintained on nutrient broth agar 
(Microbiology grade, CDH Pvt. Ltd. New Delhi) medium by 
periodic sub culturing. 
(iii) Preparation of Innoculum 
Procedure for the preparation of innoculum for both the 
strains was same. The innoculum was prepared from a 24-
hours old growth of organism on nutrient broth agar slant. 
To the agar slant, saline solution was added to obtain O.D 
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value of 0.1 on photoelectric optical colorimeter. 0.5ml of 
this solution was further diluted to 20ml with use of saline.  
(iv) Preparation of Medium 
1.3 gms of nutrient broth (Microbiology grade, CDH Pvt. Ltd. 
New Delhi.) was dissolved in 100 ml of sterile distilled 
water.  
(v) Addition of drug, innoculum solution to medium 
From diluted innoculum solution prepared, 100μl was added 
to separate test tube each containing 0.9ml of medium. 25 μl 
solution of test stock solution was added in four separate 
test tube containing 0.9ml of medium with 100 μl 
innoculum. The tests were carried out in duplicate. Apart 
from putting the controls of standard drug (Streptomycin), 
controls with dimethylsulphoxide (DMSO) were used. DMSO 
(positive control) is DMSO inoculated with organisms and 
dimethylsulphoxide (negative control) is plain DMSO. For 
incubation, test tubes were kept in incubator at 35°C for 24 
hours.  
(vi) Observations 
At the end of incubation period, the results were interpreted 
by comparison with negative control. The lowest 
concentration of test compound which showed inhibitory 
effect on growth on visual distinction was taken as minimum 
inhibitory concentration (MIC) and visual turbidity was 
consider for MIC of the test molecules; standard drug and 
DMSO positive and negative control visual turbidity were 
recorded. 
4. RESULT AND DISCUSSIONS 
4.1 Characterization of the benzothiazole derivatives: 
IR:  The spectrum showed characteristic absorption band 
accordingly of the presence of functional group. The Ar-C-H 
stretching showed the absorption band in the range of 3010-
3150 cm-1. The –C=N stretching band appeared in the range 
of 1630-1660 cm-1, -C=C- stretching peak comes in the range 
of 1400-1500 cm-1, alkyl C-H stretching peak comes in the 
range of 2820-2860 cm-1.  N-H stretching band was 
appeared in the range of 3150-3300 cm-1 
One representative molecule Compound 7b was 
characterized 1H NMR and 13C NMR spectroscopy. 
1H NMR: The methyl protons appeared as a singlet at around 
δ 2.01-1.91. The aromatic protons appeared as multiple 
singlets between δ 7.22-7.59. Representative example is 7b. 
  Sr. No. 
No of 
proton 
Predicted 
(δ in ppm) 
Experimental 
(Spectrum 5) 
1 -CH3 2.0 2.01-1.91 
3 Ar-H 7.56-8.17 7.22-7.59 
Comparison of 1H NMR values 
13C NMR: The 13C NMR values for compound 7b is listed and 
compared with the predicted values in the table below 
(Chembio office Chemdraw Ultra 8.0). Representative 
example is 7b (Spectrum 6) 
 
N
S
H
N
N
Cl
 
Structure of compound 7b 
Sr. No. 
No of 
carbon 
Predicted 
Experimental 
(Spectrum 6) 
1 CH3-C 16-22 17-25 
2 Ar-C 121-151 119-151 
3 ArC=N 169 169.9 
Comparison of 13C NMR values 
4.2 Biological evaluation 
The synthesized NCEs were subjected to antimicrobial 
evaluation against Escherichia coli and S. aureus 
microorganism using broth dilution method keeping 
appropriate positive and negative controls simultaneously. 
 Visual turbidity of evaluated compounds as in following 
Table: 
Table 1: Visual turbidity of evaluated compounds 
Sr. 
No. 
Compounds Visual Turbidity            
(E. Coli) 
Visual 
Turbidity          
(S. Aureus) 
1. 7a - - 
2. 7b - + 
3. 7c + + 
4. 7d - + 
5. 7e - - 
6. Streptomycin - - 
7 DMSO 
positive 
++ ++ 
- = No Turbidity (No bacterial growth), + = Turbidity 
(Bacterial growth) 
Based on the visual turbidity, the  MIC of the evaluated 
molecules is given in above Table the evaluation 
concentration was used single therefore, the exact MIC could 
not determined and results are represented in less than and 
more than format. To get more exact MIC of the tested 
molecules need to be evaluated at low concentration. The 
evaluation results of the single concentration is tabulated in 
Table  
Table 2: Microbiological activity results of evaluated 
compounds 
Sr. No. Compounds  E. coli 
 (µg/ml) 
 S. aureus 
(µg/ml) 
1. 7a <12.5 <12.5 
2. 7b <12.5 >12.5 
3. 7c >12.5 >12.5 
4. 7d <12.5 >12.5 
5. 7e <12.5 <12.5 
6. Streptomycin <6.25 <6.25 
 
4.3 Result of antibacterial testing 
Most of the tested compounds had bacterial growth 
inhibition activity at tested concentration against both of 
microorganisms. Compounds 7a, 7b, 7d and 7e exhibited 
growth inhibition of E.coli while 7c didn't show activity. The 
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compound 7a and 7e showed the inhibition of S. aureus and 
7b, 7c and 7d didn't show activity against S. aureus at tested 
concentration. Further testing for compounds 7a, 7b, 7d and 
7e at lower concentrations has been done to compare their 
activity with streptomycin at its MIC to find exact MIC of the 
synthesized compounds. Compound 7c was inactive against 
both of microorganisms at the tested concentration and it 
was tested at higher concentration to get the exact MIC in 
comparison of streptomycin.  
 
5. CONCLUSION 
Thus, it can be concluded that designed benzothiazole 
derivatives were synthesized successfully and compound 7a-
7e had antibacterial activity at tested concentration less than 
1000µg per ml. and compound 7a exhibited activity at lower 
concentration less than 200µg per ml. Compound 7c didn't 
show activity at higher concentration upto 1000µg per ml. 
against both Gram +ve and Gram -ve microorganisms. So, 
synthesized benzothiazole derivatives can act as a lead for 
development of broad spectrum antibacterial agents. 
 
 
6. SPECTRAS 
 
 
Spectrum 1: IR Spectra of 3 
 
Spectrum 2: IR Spectra of 5 
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Spectrum 3: IR Spectra of 7a 
 
 
Spectrum 4: IR Spectra of 7b 
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Spectrum 5: 1HNMR of 7b 
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Spectrum 6: 13C NMR of 7b 
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Spectrum 7: IR Spectra of 7c 
 
Spectrum 8: IR Spectra of 7d 
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Spectrum 9: IR Spectra of 7e 
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